A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma

Vemurafenib, a selective inhibitor of oncogenic BRAF kinase carrying the V600 mutation, is approved for treatment of advanced BRAF mutation–positive melanoma. This study characterized mass balance, metabolism, rates/routes of elimination, and disposition of (14)C-labeled vemurafenib in patients with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Pharmacol Res Perspect
Autores principales: Goldinger, Simone M, Rinderknecht, Jeannine, Dummer, Reinhard, Kuhn, Felix Pierre, Yang, Kuo-Hsiung, Lee, Lucy, Ayala, Ruben C, Racha, Jagdish, Geng, Wanping, Moore, David, Liu, Mei, Joe, Andrew K, Bazan, Selby Patricia Gil, Grippo, Joseph F
Formato: Artigo
Lenguaje:Inglês
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4324687/
https://ncbi.nlm.nih.gov/pubmed/25729580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.113
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares